These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 14630810)

  • 1. RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy.
    Coughlin CM; Vance BA; Grupp SA; Vonderheide RH
    Blood; 2004 Mar; 103(6):2046-54. PubMed ID: 14630810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ex vivo induction of viral antigen-specific CD8 T cell responses using mRNA-electroporated CD40-activated B cells.
    Van den Bosch GA; Ponsaerts P; Nijs G; Lenjou M; Vanham G; Van Bockstaele DR; Berneman ZN; Van Tendeloo VF
    Clin Exp Immunol; 2005 Mar; 139(3):458-67. PubMed ID: 15730391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy.
    Schultze JL; Michalak S; Seamon MJ; Dranoff G; Jung K; Daley J; Delgado JC; Gribben JG; Nadler LM
    J Clin Invest; 1997 Dec; 100(11):2757-65. PubMed ID: 9389740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells.
    Schmidt SM; Schag K; Müller MR; Weck MM; Appel S; Kanz L; Grünebach F; Brossart P
    Blood; 2003 Jul; 102(2):571-6. PubMed ID: 12576330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of myeloma-specific cytotoxic T lymphocytes ex vivo by CD40-activated B cells loaded with myeloma tumor antigens.
    Kim SK; Nguyen Pham TN; Nguyen Hoang TM; Kang HK; Jin CJ; Nam JH; Chung SY; Choi SJ; Yang DH; Kim YK; Chung IJ; Kim HJ; Lee JJ
    Ann Hematol; 2009 Nov; 88(11):1113-23. PubMed ID: 19277657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma.
    Mason NJ; Coughlin CM; Overley B; Cohen JN; Mitchell EL; Colligon TA; Clifford CA; Zurbriggen A; Sorenmo KU; Vonderheide RH
    Gene Ther; 2008 Jul; 15(13):955-65. PubMed ID: 18337841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells.
    Buhmann R; Nolte A; Westhaus D; Emmerich B; Hallek M
    Blood; 1999 Mar; 93(6):1992-2002. PubMed ID: 10068672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An in vitro-transcribed-mRNA polyepitope construct encoding 32 distinct HLA class I-restricted epitopes from CMV, EBV, and Influenza for use as a functional control in human immune monitoring studies.
    Nielsen JS; Wick DA; Tran E; Nelson BH; Webb JR
    J Immunol Methods; 2010 Aug; 360(1-2):149-56. PubMed ID: 20637775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel immunotherapy to hepatocellular carcinoma: CD40-activated B lymphocytes transfected with AFPmRNA.
    Wan Y; Ma X; Li X; Yi J
    Med Hypotheses; 2009 Nov; 73(5):835-7. PubMed ID: 19632790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.
    Li Q; Grover AC; Donald EJ; Carr A; Yu J; Whitfield J; Nelson M; Takeshita N; Chang AE
    J Immunol; 2005 Aug; 175(3):1424-32. PubMed ID: 16034078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autogeneic rna-electroporated CD40-ligand activated b-cells from hepatocellular carcinoma patients induce CD8+ T-cell responses ex vivo.
    Shen S; Xu Z; Qian X; Ding Y; Yu L; Liu B
    Exp Oncol; 2007 Jun; 29(2):137-43. PubMed ID: 17704747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application.
    von Bergwelt-Baildon MS; Vonderheide RH; Maecker B; Hirano N; Anderson KS; Butler MO; Xia Z; Zeng WY; Wucherpfennig KW; Nadler LM; Schultze JL
    Blood; 2002 May; 99(9):3319-25. PubMed ID: 11964299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity.
    Kalady MF; Onaitis MW; Emani S; Abdel-Wahab Z; Tyler DS; Pruitt SK
    J Surg Res; 2004 Jan; 116(1):24-31. PubMed ID: 14732346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study of combined immunotherapy with autologous adoptive tumour-specific T-cell transfer, vaccination with CD40-activated malignant B cells and interleukin 2.
    Schultze JL; Anderson KC; Gilleece MH; Gribben JG; Nadler LM
    Br J Haematol; 2001 May; 113(2):455-60. PubMed ID: 11380416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD40-activated B cells induce anti-tumor immunity in vivo.
    Wennhold K; Weber TM; Klein-Gonzalez N; Thelen M; Garcia-Marquez M; Chakupurakal G; Fiedler A; Schlösser HA; Fischer R; Theurich S; Shimabukuro-Vornhagen A; von Bergwelt-Baildon M
    Oncotarget; 2017 Apr; 8(17):27740-27753. PubMed ID: 26934557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.
    Kranz LM; Diken M; Haas H; Kreiter S; Loquai C; Reuter KC; Meng M; Fritz D; Vascotto F; Hefesha H; Grunwitz C; Vormehr M; Hüsemann Y; Selmi A; Kuhn AN; Buck J; Derhovanessian E; Rae R; Attig S; Diekmann J; Jabulowsky RA; Heesch S; Hassel J; Langguth P; Grabbe S; Huber C; Türeci Ö; Sahin U
    Nature; 2016 Jun; 534(7607):396-401. PubMed ID: 27281205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using Antigen-Specific B Cells to Combine Antibody and T Cell-Based Cancer Immunotherapy.
    Wennhold K; Thelen M; Schlößer HA; Haustein N; Reuter S; Garcia-Marquez M; Lechner A; Kobold S; Rataj F; Utermöhlen O; Chakupurakal G; Theurich S; Hallek M; Abken H; Shimabukuro-Vornhagen A; von Bergwelt-Baildon M
    Cancer Immunol Res; 2017 Sep; 5(9):730-743. PubMed ID: 28778961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells.
    Lapointe R; Bellemare-Pelletier A; Housseau F; Thibodeau J; Hwu P
    Cancer Res; 2003 Jun; 63(11):2836-43. PubMed ID: 12782589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.
    Gottschalk S; Edwards OL; Sili U; Huls MH; Goltsova T; Davis AR; Heslop HE; Rooney CM
    Blood; 2003 Mar; 101(5):1905-12. PubMed ID: 12411306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous activation of viral antigen-specific memory CD4+ and CD8+ T-cells using mRNA-electroporated CD40-activated autologous B-cells.
    Van den Bosch GA; Van Gulck E; Ponsaerts P; Nijs G; Lenjou M; Apers L; Kint I; Heyndrickx L; Vanham G; Van Bockstaele DR; Berneman ZN; Van Tendeloo VF
    J Immunother; 2006; 29(5):512-23. PubMed ID: 16971807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.